North America Drug Discovery Market Drivers, Restraints, Challenges & Opportunities, 2019-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Drug Discovery Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering.

Market Outlook

This research states that the North America drug discovery market will flourish with a CAGR of 8.36% in terms of revenue for the forecast period of 2019-2027.

The countries from the US and Canada together constitute the drug discovery market in the North American region.

North America is the fastest-growing region and is also expected to hold the largest share in the drug discovery market during the forecasted period. Growing lifestyle-oriented diseases, increasing spending on healthcare, and the adoption of the latest technology in cardiology are the major market drivers of the drug discovery market. In addition, the rising trend of outsourcing pharmaceutical manufacturing is anticipated to boost the contract research organizations (CROs) market. This will lead to the growth of the drug discovery market in the region.

The high cancer mortality rate has led to an increased demand for small molecule therapeutics in the Canadian drug discovery market. The country has significant infrastructure and expertise in manufacturing complex molecules for drug discovery. The growing scientific understanding of diseases at the molecular level and the discovery of genetic mutations, along with therapeutic efficacy of drug response, are also driving the market.

The Canadian Center of Drug Research and Development has been using high throughput screening (HTS) and chemical genomics in the Target ID and Validation (TIDV) process. Moreover, this extensive set of screening libraries of chemicals and natural product fractions guarantees a wide range of chemicals for drug activity. Also, for the automated detection of biological and biochemical activity, many such organizations use advanced technology like liquid-handling robots and instruments. These factors are expected to create lucrative opportunities for the drug discovery market.

Key Topics Covered:

1. North America Drug Discovery Market – Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter’s Five Forces Model

2.2.1. Threats of New Entrants

2.2.2. Threat of Substitute Products

2.2.3. Bargaining Power of Buyers

2.2.4. Bargaining Power of Suppliers

2.2.5. Competitive Rivalry

2.3. Pestle Outlook

2.4. Regulatory Framework

2.5. Value Chain Outlook

2.6. Market Attractiveness Index

2.7. Key Insight

2.8. Market Drivers

2.8.1. Growing Aged Population

2.8.2. Technological Advancements

2.8.3. Rise in the Healthcare Expenditure

2.8.4. Surge in Lifestyle-Oriented Diseases

2.9. Market Restraints

2.9.1. Delay in Product Launches

2.9.2. Restricting Growth Rate of A Drug Due to Generic Drugs

2.10. Market Opportunities

2.10.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities

2.10.2. Rising Demand for Specialty Medicines

2.11. Market Challenges

2.11.1. Stringent Government Regulations

3. Drug Discovery Market Outlook – By Drug Type

3.1. Small Molecule Drug

3.2. Biologic Drug

4. Drug Discovery Market Outlook – By Technology

4.1. High Throughput Screening

4.2. Biochips

4.3. Bioinformatics

4.4. Pharmacogenomics and Pharmacogenetics

4.5. Combinatorial Chemistry

4.6. Nanotechnology

4.7. Spectroscopy

4.8. Metabolomics

4.9. Other Technologies

5. Drug Discovery Market Outlook – By Service

5.1. Drug Metabolism and Pharmacokinetics (Dmpk) Services

5.2. Chemical Services

5.3. Biological Services

5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook – By End-User

6.1. Research Institutes

6.2. Pharmaceutical Companies

6.3. Contract Research Organizations (Cros)

6.4. Other End-Users

7. Drug Discovery Market – Regional Outlook

7.1. North America

7.1.1. Country Analysis

7.1.1.1. the United States

7.1.1.2. Canada

8. Company Profiles

8.1. 3M Company

8.2. Abbott Laboratories Inc.

8.3. Agilent Technologies, Inc.

8.4. Antares Pharma

8.5. Astrazeneca Plc

8.6. Bayer Ag

8.7. Becton, Dickinson and Company (Bd)

8.8. Boehringer Ingelheim

8.9. Eli Lily and Company

8.10. F. Hoffmann-La Roche Ltd.

8.11. Glaxosmithkline Llc

8.12. Johnson & Johnson

8.13. Merck & Co., Inc.

8.14. Novartis

8.15. Pfizer, Inc.

8.16. Sanofi

9. Research Methodology & Scope

9.1. Research Scope & Deliverables

9.1.1. Objectives of Study

9.1.2. Scope of Study

9.2. Sources of Data

9.2.1. Primary Data Sources

9.2.2. Secondary Data Sources

9.3. Research Methodology

9.3.1. Evaluation of Proposed Market

9.3.2. Identification of Data Sources

9.3.3. Assessment of Market Determinants

9.3.4. Data Collection

9.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/uml6lr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900